Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies.

about

Anticancer drugs for the modulation of endoplasmic reticulum stress and oxidative stress HIF-1α pathway: role, regulation and intervention for cancer therapy.

P2860

Q26799265-739B0650-ED97-42C1-9FDC-D930CC5C8A21 Q36238647-D4020370-B6B1-43B9-841E-C317C2EDBB1E

P2860

Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies.

Item

http://www.wikidata.org/entity/Q41135739

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Preclinical evaluation of bort ...... for hematologic malignancies.

@en

type

Item

label

Preclinical evaluation of bort ...... for hematologic malignancies.

@en

prefLabel

Preclinical evaluation of bort ...... for hematologic malignancies.

@en

P1476

Preclinical evaluation of bort ...... for hematologic malignancies.

@en

P2093

Bo-Yeon Kim

http://www.w3.org/2001/XMLSchema#string

Jong-Seog Ahn

http://www.w3.org/2001/XMLSchema#string

Raymond L Erikson

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Sakai

http://www.w3.org/2001/XMLSchema#string

P2860

Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.

BID binds to replication protein A and stimulates ATR function following replicative stress

Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.

Total cost comparison in relapsed/refractory multiple myeloma.

The BCL-2 family reunion.

P304

309-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MOLONC.2014.08.010

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ahmed E Goda

P577

2014-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25245324

http://www.w3.org/2001/XMLSchema#string

P932

5528671

http://www.w3.org/2001/XMLSchema#string

Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies.

about

P2860

P2860

Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932